|
|
Allies in the Race Against Time: Navigating Alzheimer's Disease with Early Detection, Therapeutic Innovations, and Patient-Centric Care " Module Three
Target Audience
This activity is designed to meet the educational needs of healthcare professionals who provide care for patients primary care clinicians including internists, family physicians, radiologists, neurologists, nurse practitioners and physician assistants
Program Overview
Alzheimer's disease (AD) is a progressive and devastating neurodegenerative disorder that affects a significant portion of the elderly population and is increasing globally. Recent advancements in diseas... |
|
|
Allies in the Race Against Time: Navigating Alzheimer's Disease with Early Detection, Therapeutic Innovations, and Patient-Centric Care " Module Four
Target Audience
This activity is designed to meet the educational needs of healthcare professionals who provide care for patients primary care clinicians including internists, family physicians, radiologists, neurologists, nurse practitioners and physician assistants.
Program Overview
Alzheimer's disease (AD) is a progressive and devastating neurodegenerative disorder that affects a significant portion of the elderly population and is increasing globally. Recent advancements in disea... |
|
|
Improving Alzheimer’s Disease Management: Updates on Patient Diagnosis and Treatment
The face of mild cognitive impairment (MCI) and Alzheimer’s disease (AD) diagnosis and management is rapidly changing. A growing understanding of AD pathophysiology has shaped research of targeted therapies and helped clinicians better understand the causes of the disease and the utility of biomarkers. Though cognitive testing is still a critical component of diagnosis, it no longer stands alone. Biomarkers are increasingly incorporated into practice to aid in diagnosis of MCI and AD and to ... |
|
|
Across the Compendium: Practical Pathways to Integrate Bispecific Antibodies Into Care for Patients With Relapsed/Refractory Multiple Myeloma
As the armamentarium of therapies for relapsed/refractory multiple myeloma (R/R MM) expands, several factors, including previous therapy, treatment-related toxicity, and comorbidities must be considered as part of clinical decision making. To assist the multidisciplinary treatment team in these efforts, and ensure patients are receiving cutting-edge cancer care, this immersive digital practice guide highlights best practices, clinical pearls, and strategies to overcome pitfalls in the administ... |
|
|
Top 10 Questions on Biomarkers in Early Alzheimer’s Disease: Improving Diagnosis and Use of Targeted Therapies
The past several years have seen numerous advances in Alzheimer’s disease (AD) diagnosis and management. Most recently, approval of antiamyloid monoclonal antibodies has revolutionized AD management and has required that patients have amyloid burden verified prior to initiating treatment. Biomarkers, whether obtained from cerebrospinal fluid (CSF) or positron emission tomography (PET) scans, are critical to the early diagnosis of AD and its subsequent management. Plasma biomarkers are an eme... |
|
|
Recurrent and Metastatic HNSCC: New Insights and Real-World Evidence for Improved Patient Outcomes
STATEMENT OF NEED
Head and neck cancers represent a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 66,470 new cases are diagnosed in the United States annually, and 15,050 people die of the disease (Siegel et al, 2022). Approximately 90% of cases are classified as head and neck squamous cell carcinoma (HNSCC). Treatment of HNSCC is complicated by numerous factors, including differing therapeutic strategies ... |
|
|
Case Studies in Multiple Sclerosis and Aging
• Identify the clinical difference between age-related/neurodegenerative cognitive decline and MS-related cognitive impairment.
• Discuss the role of potential biomarkers in identifying coexisting neurodegenerative disorders.
• Explain why it is important for the care team to address comorbid vascular risk factors for cognitive decline, including lifestyle modification and healthy behaviors
https://academycme.org/pdfs/MSAging.pdf |
|
|
Keeping Up with the Evolving Treatment Landscape for Advanced/Metastatic Gastric/GEJ Cancer: Modeling Center of Excellence Practices
Are you optimally treating your patients with gastric/gastroesophageal junction (GEJ) cancers per the latest evidence on selection of therapies? Despite recent advancements in diagnosis of gastric/GEJ cancer, most cases are detected at advanced stages, resulting in poor outcomes. But advances have identified biomarkers that can offer more precise diagnostic and therapeutic approaches for gastric/GEJ cancer patients. In addition to HER2 and PD-L1 status, microsatellite instability (MSI) status... |
|
|
Alzheimer’s Disease & Dementia: A Practical Guide
Alzheimer’s Disease and Dementia: A Practical Guide is a 3-hour online continuing education (CE) course that offers healthcare professionals a basic foundation in Alzheimer's disease prevention, diagnosis, and risk management through a literature review of evidence-based information and best practices.
Practical information to aid healthcare professionals as they interact with clients who are diagnosed with any of the many types of dementia is presented. For the purposes of this cour... |
|